Testing for amphetamine, methamphetamine, and amphetamine-like compounds focuses primarily on detection of amphetamine, methamphetamine, and designer drugs often grouped together as ecstasy (MDMA, MDA, and MDEA). The primary concern for immunoassay screening is false-positive results due to cross-reactivity of the reagent antibodies to other sympathomimetic amines, namely, the hydroxyl amines ephedrine, pseudoephedrine, and phenylpropanolamine. For GC/MS confirmation testing, generation of methamphetamine from high levels of pseudoephedrine or ephedrine in injection ports at high temperatures after derivatization with 4-CB, HFBA, and TPC is a potential problem. Periodate treatment of samples prior to immunoassay screening or GC/MS confirmation removes the interfering sympathomimetic amines. Another problem with amphetamines testing is the existence of d and I stereoisomers that are not distinguishable by immunoassay screening and most GC/MS confirmation procedures. Isomer resolution procedures involve separation using chiral columns or derivatization using optically pure chiral derivatizing agents. Testing for amphetamine, methamphetamine, and MDMA/metabolites in hair, oral fluid, and sweat presents matrix-specific problems and introduction of other confirmation methods involving LC and MSMS instrumentation.

Drug Free Life

Drug Free Life

How To Beat Drugs And Be On Your Way To Full Recovery. In this book, you will learn all about: Background Info On Drugs, Psychological Treatments Statistics, Rehab, Hypnosis and Much MORE.

Get My Free Ebook

Post a comment